To determine whether metformin hydrochloride (MET) added to chemoradiotherapy can improve progression-free survival (PFS) at 12 months in patients with locally advanced non-small cell lung cancer (NSCLC).
Clinical Trial Information
Trial Contact: Morales, Leticia; Picart, Roger
Age Group: Adult
Phase: Drug: Phase II
Principal Investigator: Justin Mathew Rineer, MD
Secondary Protocol No: LU001
Applicable Disease Sites: Head and Neck